Hercent Tablet 40 mg contains Neratinib Maleate, an oral tyrosine kinase inhibitor (TKI) designed for the treatment of HER2-positive breast cancer. It is particularly indicated as an extended adjuvant therapy in patients who have completed trastuzumab-based therapy, helping to reduce the risk of cancer recurrence. Hercent targets the human epidermal growth factor receptor 2 (HER2) pathway, which is overexpressed in certain aggressive breast cancers, thereby inhibiting tumor growth and proliferation.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Hercent Tablet 40 mg is indicated for:

• Extended adjuvant treatment of early-stage HER2-positive breast cancer following completion of trastuzumab therapy

• Treatment of HER2-positive metastatic breast cancer in select patients, often in combination with other therapies

• Reduction of risk of cancer recurrence in high-risk individuals with HER2-positive tumors

This therapy is suitable for adults with HER2-positive breast cancer, confirmed by FDA-approved diagnostic tests.

Therapeutic Class

• Targeted Cancer Therapy

• Tyrosine Kinase Inhibitor (HER2)

Pharmacology

Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that targets HER1 (EGFR), HER2, and HER4 receptors. By binding to the intracellular kinase domain, Neratinib prevents autophosphorylation of HER receptors, inhibiting downstream signaling pathways such as Ras/Raf/MEK/ERK and PI3K/AKT. This results in:

• Suppression of tumor cell proliferation

• Induction of apoptosis in malignant cells

• Inhibition of HER2-driven tumor growth

As an irreversible inhibitor, Neratinib provides prolonged suppression of HER2 signaling, which is associated with reduced recurrence in patients with HER2-positive breast cancer.

Dosage and Administration

• Recommended dose: 40 mg orally once daily

• Take with food to enhance absorption and reduce gastrointestinal side effects

• Therapy is continued for up to 12 months as extended adjuvant treatment, unless unacceptable toxicity occurs

• If a dose is missed, take it as soon as possible; do not double the next dose

Administration tips:

• Swallow tablets whole with water; do not crush or chew

• Regular monitoring of liver function, complete blood counts, and electrolytes is advised

Drug Interactions

• CYP3A4 inducers (e.g., rifampicin, phenytoin) may reduce plasma Neratinib levels and efficacy

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase toxicity

• Caution with medications affecting gastric pH (e.g., PPIs, H2 blockers), as they may reduce absorption

• May interact with anticoagulants such as warfarin, requiring monitoring

Contraindications

• Known hypersensitivity to Neratinib or any component of the formulation

• Severe hepatic impairment

• Pregnancy and lactation without medical supervision

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common adverse effects include:

• Diarrhea, nausea, vomiting, and abdominal pain

• Fatigue, headache, and rash

• Elevated liver enzymes (ALT, AST)

• Rare but serious: hepatotoxicity, interstitial lung disease, QT prolongation

Patients are advised to maintain hydration and report persistent gastrointestinal symptoms.

Precautions and Warnings

• Diarrhea prophylaxis: Often managed with antidiarrheal agents such as loperamide at therapy initiation

• Monitor liver function tests periodically

• Use effective contraception during and up to 3 weeks after therapy due to embryo-fetal toxicity

• Closely monitor cardiac function in patients at risk of QT prolongation

Pregnancy and Lactation

• Pregnancy category D: Neratinib may cause fetal harm

• Avoid breastfeeding during therapy

Storage Conditions

• Store at 20–25°C in a dry place

• Protect from moisture and light

• Keep out of reach of children.